Início › Câncer de Mama › Virgínia
Ensaios clínicos de Câncer de Mama em Virgínia
77 estudos para Câncer de Mama estão buscando participantes em locais em Virgínia.
Cidades em Virgínia
- Arlington46 estudos
- Richmond26 estudos
- Norfolk16 estudos
- Charlottesville9 estudos
- Roanoke7 estudos
- Alexandria6 estudos
- Winchester5 estudos
- Waynesboro4 estudos
- Lynchburg4 estudos
- Newport News3 estudos
- Fredericksburg3 estudos
Texto oficial do estudo (Inglês)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Bon Secours Virginia Health System, Midlothian
- Virginia Oncology Associates, Norfolk
RecrutandoFase 3
Idades de 18 a 100 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- e mais 7
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Virginia Oncology Associates, Norfolk
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07701941A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
- Shenandoah Oncology, Winchester
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07102381A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Virginia Cancer Institute, Richmond
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06369285Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, PC, Fairfax
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de set. de 2026 · NCT06324357Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Inova Schar Cancer Institute, Fairfax
RecrutandoFase 3
Idades 19 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05856773Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Inova Schar Cancer Institute, Fairfax
- Hampton University Proton Therapy Institute, Hampton
RecrutandoFase 2
Idades 50 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT01766297Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05867251A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
- Shenandoah Oncology ( Site 8004), Winchester
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT07060807A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Inova Schar Cancer Institute ( Site 0025), Fairfax
- Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian
- VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond
- e mais 1
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Charlottesville
- Research Site, Fairfax
- Research Site, Midlothian
- e mais 2
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Virginia Cancer Specialists, Fairfax
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Fort Belvoir
- Clinical Trial Site, Midlothian
- Clinical Trial Site, Norfolk
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Inova, Fairfax
Recrutando
Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Virginia Cancer Specialists, Fairfax
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174336Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
- Adult Outpatient Pavilion, Richmond
- Cellular Immunotherapies and Transplant Department, Richmond
- VCU Health at Stony Point, Richmond
Recrutando
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07426913A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Virginia Health System, Charlottesville
- Inova Schar Cancer Institute, Fairfax
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07287098A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Next Virginia, Fairfax
RecrutandoFase 1
Idades 18 e acima · Mulheres · Atualizado em 21 de set. de 2026 · NCT07524855ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Bon Secours Cancer Institute at Memorial Regional, Mechanicsville
- Bon Secours St. Francis Medical Center, Midlothian
- Bon Secours Cancer Institute at St. Mary's, Richmond
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Newport News
- e mais 2
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06253871A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- NEXT Oncology, Fairfax
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06440005Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Virginia Cancer Institute, Norfolk
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT05386108A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Midlothian
RecrutandoFase 3
Idades de 18 a 130 · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07100106Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Virginia Cancer Specialists-Fairfax, Fairfax
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07287917Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Next Oncology, Fairfax
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Virginia Cancer Specialists, PC, Fairfax
- Virginia Oncology Associates, Norfolk
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06982521A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- NEXT Virginia, Fairfax
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT07287995The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- e mais 5
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Kaiser Permanente-Burke Medical Center, Burke
- University of Virginia Cancer Center, Charlottesville
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- e mais 12
RecrutandoFase 3
Idades de 18 a 60 · Mulheres · Atualizado em 2 de set. de 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06072612A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Virginia, Fairfax
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT07029399A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- NEXT Virginia, Fairfax
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 26 de ago. de 2026 · NCT07383506Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.